At a Glance

Why It's Ordered
Bleeding or a clotting disorder, anticoagulant effect, and suspected disseminated intravascular coagulation (DIC) in trauma, hemorrhage, sepsis or liver failure.
Check First
PT/INR and fibrinogen first: a high INR points to warfarin or liver failure; low fibrinogen with a high D-dimer points to consumption, DIC or dilution. Add aPTT and platelets for heparin, HIT and massive transfusion.
Critical Values
INR >5.0 · Fibrinogen <100 mg/dL · aPTT ≥100 s · Platelets <30 or >1,000 ×10³/µL
Don't Miss
A normal PT/INR and aPTT do not exclude a clinically important apixaban or edoxaban effect. Check the last-dose time and treat major bleeding per protocol.
Field & Transport
Fingerstick POC INR is approximate and less reliable at high values and with antiphospholipid antibodies; confirm on laboratory blood. Draw the light blue tube by fresh venipuncture away from heparin lines or flushes, filled to the line; treat major warfarin bleeding per protocol.

Panel Overview

The coagulation panel is four measured tests: prothrombin time with INR (PT/INR), activated partial thromboplastin time (aPTT), fibrinogen and D-dimer. It is drawn in the ED for bleeding or clotting, in the ICU for anticoagulant monitoring and DIC, and before transfer for major bleeding. Platelet count is a related test on the CBC. It is included on the cards because it changes bleeding management.

When to Order:
  • Bleeding on an anticoagulant: warfarin, heparin, DOAC or after reversal
  • Trauma or hemorrhage: massive transfusion and coagulopathy
  • Sepsis or suspected DIC: bleeding or purpura with a falling platelet count
  • Liver failure: bleeding or pre-procedure assessment
  • Thrombosis: D-dimer for suspected VTE in lower-risk patients
  • Heparin monitoring: aPTT or anti-Xa on UFH or LMWH, or a platelet fall after heparin

Clotting Times

PT/INR

Normal: PT 11–13.5 s | INR 0.8–1.1

Extrinsic and common pathways. Raised by warfarin, liver failure, vitamin K deficiency, DIC and rivaroxaban. INR standardizes PT for warfarin: 2.0–3.0 usual, 2.5–3.5 mechanical mitral.

Learn More

aPTT

Normal: 25–35 s

Intrinsic and common pathways. Prolonged by UFH, argatroban, hemophilia A or B and lupus anticoagulant. Normal does not exclude a clinically important apixaban effect.

Learn More

Clot Formation & Breakdown

Fibrinogen

Normal: 200–400 mg/dL

Clot substrate. Falls in massive hemorrhage, dilution, DIC and fibrinolysis; rises in pregnancy and inflammation. Replace when bleeding and below about 150 mg/dL (trauma) or 200 mg/dL (postpartum hemorrhage).

Learn More

D-dimer

Normal: <500 ng/mL FEU

Fibrin breakdown product. A negative result with low pretest probability excludes VTE; a positive result is nonspecific. Raised in DIC, sepsis, trauma and age over 50.

Learn More

Related Hemostasis Tests

Platelet Count

Normal: 150–400 ×10³/µL

Falls with consumption (DIC, TTP, HIT), marrow failure, dilution and ITP. Keep above 50 ×10³/µL during ongoing trauma bleeding.

Learn More

Anti-Xa

Therapeutic: UFH 0.3–0.7 units/mL; LMWH and DOAC per assay and protocol

Factor Xa inhibition by heparin, LMWH, fondaparinux or a drug-calibrated DOAC level. Preferred over aPTT for LMWH monitoring.

Learn More

TEG / ROTEM

Expected: assay-specific, no universal range

Whole-blood clot strength and fibrinolysis over time. Guides product use in trauma and surgery; do not delay tranexamic acid or massive transfusion while waiting for results.

Learn More

HIT Antibody (PF4)

Expected: negative; assay-specific

PF4/heparin immunoassay sent with the 4Ts score for a platelet fall after heparin. Not sent for a low 4Ts score; a positive result alone does not confirm HIT.

Reference Ranges & Critical Values
Lab-specific ranges: Every lab, analyzer and assay sets its own interval and its own critical list. Go by the range your lab reports and its critical-call policy.
TestAdult Normal (conventional)SI UnitsCritical LowCritical HighNotes
PT
11–13.5 s
11–13.5 s
—
—
Reagent-specific; use lab range
INR
0.8–1.1
Dimensionless
—
>5.0
Warfarin 2.0–3.0; 2.5–3.5 mechanical mitral
aPTT
25–35 s
25–35 s
—
≥100 s
Typical critical value set by lab policy; lab-calibrated; UFH range per lab
Fibrinogen
200–400 mg/dL
2–4 g/L
<100 mg/dL
—
Higher in pregnancy and inflammation
D-dimer
<500 ng/mL FEU
<500 µg/L FEU
—
—
Age × 10 over 50; assay-specific
Platelets
150–400 ×10³/µL
150–400 ×10⁹/L
<30
>1,000
Some labs extend normal to 450
UFH anti-Xa
0.3–0.7 units/mL
Same
—
—
Therapeutic range, not normal

Critical values are a typical set, and each institution sets its own. Pediatric ranges live in Special Populations.

Systematic Interpretation
  1. Context first: Find out which anticoagulant was given, the drug and dose, and when the last dose was given (warfarin, UFH, enoxaparin, apixaban, rivaroxaban, edoxaban, dabigatran, argatroban). Note the bleeding site, liver disease, pregnancy and any line draw.
  2. PT/INR: Treat a high INR with bleeding on warfarin as warfarin until proven otherwise. Liver failure, vitamin K deficiency, DIC and rivaroxaban can all raise it too. The PT response to a DOAC depends on the drug.
  3. aPTT: UFH, argatroban, bivalirudin, dabigatran, hemophilia A or B and a lupus anticoagulant all prolong it. A normal aPTT does not rule out an apixaban or edoxaban effect that matters clinically.
  4. Pattern: Sort the result into a bucket: isolated PT, isolated aPTT or both prolonged (Patterns & Differential table).
  5. Fibrinogen and platelets: Low fibrinogen with a falling platelet count points to consumption, dilution or DIC. Once there is active hemorrhage, the replacement trigger is about 150 mg/dL in trauma (2023 European trauma guideline) or about 200 mg/dL in postpartum hemorrhage. Details are in Critical Findings.
  6. D-dimer and DIC score: Score the ISTH overt DIC criteria only in a patient with a DIC-associated condition: sepsis, trauma, malignancy or an obstetric emergency. Repeat it daily.
ISTH overt DIC score (2001 criteria; 2025 update under review)
Platelets: <50 ×10⁹/L = 2; 50 to <100 = 1 · D-dimer: moderate increase (about 3× ULN) = 2; strong increase (about 7× ULN or more) = 3 · PT prolongation: 3 to <6 s = 1; ≥6 s = 2 · Fibrinogen <1 g/L = 1

Score 0–8. These points come from the 2001 score and have not yet been checked against the 2025 update text. A total of 5 or more fits overt DIC. A lower total does not rule DIC out. Repeat the score and look at the whole picture.

Worked Example: A septic patient with platelets 92 ×10³/µL scores 1. D-dimer at 4× ULN scores 2. PT 4 s above control scores 1. Fibrinogen of 90 mg/dL, or 0.9 g/L, scores 1. That totals 5, which meets the overt DIC threshold. Treat the sepsis source. Replace products by bleeding and target. The score alone does not decide it.

Patterns & Differential

Read each pattern against the patient in front of you. One result can have several causes, so the picture decides which one it is.

PatternKey FindingsCommon CausesNext Step
Isolated prolonged PT/INR
aPTT normal
Warfarin, rivaroxaban, vitamin K deficiency, early liver disease, factor VII deficiency
Warfarin dose and last-dose time; vitamin K or 4F-PCC per bleeding
Isolated prolonged aPTT
PT normal
UFH, argatroban, bivalirudin, lupus anticoagulant, hemophilia A or B
Heparin history; anti-Xa for UFH; hematology for factor deficiency
Both PT and aPTT prolonged
Fibrinogen often low
DIC, liver failure, massive transfusion, dilution, sepsis
Fibrinogen, platelets, D-dimer; ISTH score; replace by bleeding
Low platelets, schistocytes, neurologic or renal signs
PT/aPTT often normal
TTP, HUS, HELLP, preeclampsia
Peripheral smear; urgent hematology; ADAMTS13 per lab
Platelet fall after heparin exposure
Thrombosis may be present
Heparin-induced thrombocytopenia (HIT)
4Ts score; stop heparin including flushes; non-heparin anticoagulant (2018 ASH HIT guideline)
Elevated D-dimer, normal fibrinogen and platelets
Clinical picture decides
Pulmonary embolism, DVT, aortic dissection, recent surgery, pregnancy
Pretest probability first; image per PE pathway (2019 ESC PE guideline)

Serial Testing & Kinetics

Protocols set the monitoring intervals. The targets are the bleeding-control thresholds this page uses elsewhere.

AnalyteRises or EffectPeakRepeat / ReturnMonitoring Target
UFH aPTT or anti-Xa
Within minutes of an IV bolus
—
About 6 h after start or rate change, then per protocol
Lab heparin aPTT range; anti-Xa 0.3–0.7 units/mL
INR after reversal
Warfarin effect reverses within hours
—
Recheck 6–8 h after IV vitamin K; 12–48 h after oral
Falling INR; repeat per bleeding
Fibrinogen after replacement
Rises after each product dose
—
Recheck after each dose or per protocol
Trauma: about 150 mg/dL (1.5 g/L) or viscoelastic deficiency; PPH: about 200 mg/dL (2 g/L)
Platelets after transfusion
Rises after each unit
—
Recheck per protocol during ongoing bleeding
Above 50 ×10³/µL in trauma bleeding; above 100 in TBI

Critical Findings & Emergency Actions

Major bleeding on a vitamin K antagonist (warfarin)

Recognize: The INR is above target and the bleeding is major or intracranial.

  1. Airway, breathing, circulation: Pressure and a tourniquet control the bleeding. Call the receiving team or medical control too.
  2. Labs: Draw an INR, a CBC, fibrinogen and a type and crossmatch if you can. Treatment does not wait for results.
  3. 4-factor PCC: Dose per protocol from the Kcentra label, by INR and weight: 25 units/kg for INR 2 to under 4 (max 2,500 units), 35 units/kg for INR 4 to 6 (max 3,500 units), 50 units/kg for INR above 6 (max 5,000 units). That maximum holds up to 100 kg. Repeat dosing is not recommended, because its safety and effectiveness are not established. Boxed warning: arterial and venous thromboembolic complications. Watch for thrombosis. Track the INR and the clinical response during and after treatment. Contraindicated with known heparin-induced thrombocytopenia, because the product contains heparin, and with disseminated intravascular coagulation (DIC). Protocol-dependent.
  4. IV vitamin K (RN): Vitamin K 5–10 mg IV, diluted, no faster than 1 mg/min. The Kcentra label says to give it with the PCC. That keeps the INR from rebounding. Boxed warning: IV use carries a risk of severe hypersensitivity and anaphylactoid reactions. The IV route is for life-threatening bleeding only. Watch closely. Vitamin K alone works too slowly for that kind of bleed.
  5. Plasma only if PCC is unavailable: 10–15 mL/kg fresh frozen plasma per the 2020 ACC pathway. If PCC is on hand, plasma does not replace it.

Hemorrhage with low fibrinogen, platelets or ionized calcium

Recognize: Ongoing bleeding from trauma, hemorrhagic shock or postpartum hemorrhage. Watch for fibrinogen below about 150 mg/dL in trauma or 200 mg/dL in postpartum hemorrhage, platelets below 50 ×10³/µL, or ionized calcium below 1.1 mmol/L.

  1. Tranexamic acid early (Paramedic/RN): Tranexamic acid 1 g IV/IO over 10 min, then 1 g over 8 hr, within 3 hr of injury (adult dose). Labs do not hold it up.
  2. Fibrinogen (RN): In trauma, replace when fibrinogen is below about 1.5 g/L (150 mg/dL), or when viscoelastic testing shows a deficiency (2023 European trauma guideline). For postpartum hemorrhage, the obstetric trigger is about 2 g/L (200 mg/dL). Use cryoprecipitate or fibrinogen concentrate per protocol. Recheck after every dose.
  3. Platelets: Keep the count above 50 ×10³/µL while trauma bleeding continues. With traumatic brain injury, the target rises to above 100 ×10³/µL (2023 European trauma guideline).
  4. Ionized calcium: Keep it inside the normal range (1.1–1.3 mmol/L) through massive transfusion. Give calcium chloride per protocol.

Bleeding after unfractionated heparin or enoxaparin

Recognize: Bleeding, plus a prolonged aPTT or a recent heparin dose.

  1. Count only heparin still circulating: UFH bolus within 30 min: 1 mg per 100 units; 30–60 min: 0.5–0.75 mg per 100 units; 60–120 min: 0.375–0.5 mg per 100 units; more than 120 min: 0.25–0.375 mg per 100 units. Maximum 50 mg per dose, slow IV, no more than 50 mg in any 10 min. Protamine boxed warning: severe hypotension, cardiovascular collapse, non-cardiogenic pulmonary edema, pulmonary vasoconstriction and pulmonary hypertension. Risk is higher with rapid dosing, prior protamine, NPH insulin, fish allergy or prior vasectomy. Have resuscitation ready.
  2. Enoxaparin: 1 mg per 1 mg enoxaparin if the last dose was 8 hr ago or less; 0.5 mg per 1 mg if 8–12 hr ago; protamine may not be needed more than 12 hr after the dose. Maximum 50 mg per dose. If aPTT stays prolonged 2–4 hr after the first dose, a second 0.5 mg per 1 mg dose may be given. Protamine only partly reverses enoxaparin.
  3. Repeat by aPTT or anti-Xa per protocol. Protamine does not touch fondaparinux, argatroban, bivalirudin or any DOAC.

Suspected heparin-induced thrombocytopenia

Recognize: Platelets fall during or after heparin exposure, with or without thrombosis. Score the 4Ts first.

  1. Stop all heparin: Infusions, flushes, lock solutions and heparin-coated catheters all count, per local protocol.
  2. Start a non-heparin anticoagulant at therapeutic intensity when the 4Ts score is high or intermediate. Follow hematology and the 2018 ASH guideline. For PCI with acute HIT, bivalirudin is the preferred choice.
  3. Send the PF4 immunoassay per protocol. Per hematology, platelets for HIT are given only when bleeding requires them.

Major bleeding on a direct oral anticoagulant

Recognize: Major bleeding in a patient on apixaban, rivaroxaban, edoxaban or dabigatran.

  1. Dabigatran: Give idarucizumab 5 g IV as two consecutive 2.5 g doses (two vials or infusions). Per protocol, dialysis may be considered.
  2. Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban): When andexanet alfa is not on hand, 4-factor PCC is the usual choice. Per the 2020 ACC pathway, that is about 2,000 units fixed dose or 25–50 units/kg, protocol-dependent. Per protocol, activated PCC is an alternative. Andexanet alfa is not dependable. Check local stocking and the current manufacturer notice.
  3. Supportive care: Hold the next dose. Activated charcoal may be considered per protocol if the last dose was recent. Tranexamic acid is adjunctive and off-label for DOAC bleeding. It is not a reversal agent. Check the last-dose time and renal function.

Doses vary by protocol; follow local protocols and medical direction.

Prehospital & Transport Considerations

Point-of-Care Testing

A field test tells you whether the patient is coagulopathic. It does not tell you the reversal dose. The bleeding and the last-dose history decide treatment.

Device or MethodAnalytesLimitations
Fingerstick POC INR meter
INR (capillary)
Accuracy falls at higher INRs and with antiphospholipid antibodies; confirm high or surprising values on a laboratory sample.
Hospital viscoelastic test (TEG or ROTEM)
Clot strength and fibrinolysis over minutes
Hospital only; assay-specific ranges; do not delay tranexamic acid or products while waiting.
Field glucometer, lactate, blood gas
Not coagulation tests
Use for the bleeding workup only as context, never as a coagulation result.

Interfacility Transfer & Handoff

  • Send with the patient: The last anticoagulant or antiplatelet dose and its time. The reversal given, with drug, dose and time. Any blood products too.
  • Labs to obtain: INR or PT, aPTT, fibrinogen, platelets, CBC and type and crossmatch before transfer when possible, and the results and times.
  • Repeat en route: Recheck bleeding, mental status and vitals after each product or reversal dose. The INR does not change quickly after PCC on the way.
  • Specimen handling: Keep blue-top tubes at room temperature and get them processed quickly. A flight cooler or cold chain can change the results.

Scope Notes

  • Paramedic: Pressure, a tourniquet, transport and notification are the core actions. Tranexamic acid in trauma is per local protocol.
  • RN and CCT: Reversal agents, vitamin K, PCC and blood products are per protocol and medical direction.

Special Populations

Pediatrics

PT/INR and aPTT ranges change with age, so use the lab's age range. Pediatric critical values follow the same typical thresholds unless the lab specifies otherwise.

TestNeonate (term)Infant and ChildAdolescent
PT/INR
INR 1.1–1.7 (37–39 wk); 1.2–1.8 (40–42 wk)
Lab age-specific range; close to adult after early infancy
0.8–1.1
aPTT
28–43 s (37–39 wk); 24–38 s (40–42 wk)
Lab age-specific range; close to adult after infancy
25–35 s
Fibrinogen
Use the lab neonatal range (not adult)
Same as adult; use the lab age range
200–400 mg/dL
Platelets
150–400 ×10³/µL
150–400 ×10³/µL
150–400 ×10³/µL
  • Vitamin K: Newborn prophylaxis is one weight-based dose. The vitamin K page gives the schedule. Active VKDB bleeding is an emergency. It needs IV vitamin K and urgent medical direction.
  • Tranexamic acid (off-label; trial-derived): 15 mg/kg IV/IO (max 1 g) over 10–20 min, then 2 mg/kg/hr for 8 hr (max 1 g total infusion), within 3 hr of injury. Follow the pediatric trauma or hemorrhage protocol. There is no standardized prehospital pediatric dose.
  • Protamine: Dosing is not weight-based. Use the heparin time bands above, with a maximum of 50 mg per dose. The label says safety and efficacy in children are not established.

See Weight-Based Dosing and Pediatric Vital Signs.

Pregnancy

  • Fibrinogen rises by trimester: 244–510 mg/dL (1st), 291–538 mg/dL (2nd), 373–619 mg/dL (3rd). A value that is normal for a nonpregnant adult can read low at term.
  • D-dimer rises through pregnancy. There is no trimester-specific rule-out cutoff.
  • Postpartum hemorrhage: Tranexamic acid 1 g IV over 10 min within 3 hr of birth. It goes with uterotonics, never instead of them.
  • Anticoagulation: Warfarin crosses the placenta, so it is generally avoided. LMWH is the usual choice.

Older Adults

  • D-dimer: Over 50 years, the suspected pulmonary embolism cutoff is age × 10 ng/mL FEU (2019 ESC PE guideline).
  • Anticoagulant use: Most bleeding in older adults involves DOACs or warfarin. Check the last dose and renal function.

CKD and Dialysis

  • Enoxaparin accumulates when renal function is reduced. Check the enoxaparin page for dose adjustment.
  • Dialysis: Heparin in the circuit prolongs the aPTT. Read results with that circuit anticoagulation in mind.

Specimen Collection & Interfering Factors
  • Tube: Light blue, with 3.2% sodium citrate. Tube colors and additives vary by institution.
  • Fill: Fill to the line for a citrate-to-blood ratio of 9:1. An underfilled tube falsely prolongs PT and aPTT.
  • Handling: Invert gently to mix. Process promptly per laboratory policy. Factor VIII and V results drift when the tube waits.
  • Order of draw (CLSI GP41): Blood cultures, then light blue, then red or gold, then green, then lavender, then gray.
InterferentEffect on ResultsPrevention
Underfilled tube
Excess citrate; falsely long PT and aPTT
Fill to the line; redraw if short
Heparin contamination
Prolonged aPTT; falsely abnormal results
Draw by fresh venipuncture away from heparin lines and flushes
Line draw or IV fluid dilution
Low factor levels and prolonged times
Stop infusions; draw from a clean site per policy
DOAC in the sample
Prolonged PT or aPTT, drug-dependent; apixaban often barely changes them
Record drug and last-dose time; use a drug-calibrated assay
Lupus anticoagulant
Prolonged aPTT that does not correct on mixing
Flag to laboratory; use chromogenic assays where needed
Antiphospholipid antibodies
Falsely high INR on some POC meters
Confirm with laboratory INR
Delayed processing
Factor VIII and V results fall
Process promptly per laboratory policy

Clinical Pearls
INR is for warfarin. The standardization exists to monitor vitamin K antagonists. In trauma, the prothrombin time ratio (PTr) marks coagulopathy. Above 1.2 is coagulopathic. Above 1.5 is severe (2023 European trauma guideline).
Normal fibrinogen is not normal hemostasis. Fibrinogen is an acute-phase reactant. A value that looks adequate in a bleeding patient can still sit below the replacement trigger: about 150 mg/dL in trauma or about 200 mg/dL in postpartum hemorrhage.
Use the age-adjusted D-dimer cutoff. Over 50 years, the suspected pulmonary embolism cutoff is age × 10 ng/mL FEU. A negative D-dimer with low pretest probability excludes VTE. It cannot rule VTE in.
Viscoelastic results do not gate tranexamic acid. TEG and ROTEM steer product choices. They do not decide whether to give tranexamic acid in trauma or PPH.
The aPTT is a poor LMWH monitor. For enoxaparin or dalteparin, the usual test is anti-Xa. For UFH, use the lab aPTT or anti-Xa per protocol.
Field: coagulopathy is clinical first. A bleeding patient on warfarin needs reversal based on history and bleeding site. The POC INR can be wrong, and it must not delay treatment.
Pitfall: Plasma instead of PCC. Fresh frozen plasma corrects the INR slowly, and it takes large volumes to do it. For major warfarin bleeding, use 4-factor PCC when it is available, with IV vitamin K.
Pitfall: DIC score in the wrong patient. The ISTH overt DIC score applies only when a DIC-associated condition is present. Do not score routine anticoagulant bleeding as DIC.

Related

References
  1. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2020;76(5):594–622. https://www.jacc.org/doi/10.1016/j.jacc.2020.04.053
  2. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage. Stroke. 2022;53(7):e282–e361. https://www.ahajournals.org/doi/10.1161/STR.0000000000000407
  3. Rossaint R, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. 2023;27:80. https://link.springer.com/article/10.1186/s13054-023-04327-7
  4. Iba T, Levy JH, Maier CL, et al. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025. https://pubmed.ncbi.nlm.nih.gov/40829630/
  5. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–3392. https://ashpublications.org/bloodadvances/article-pdf/2/22/3360/883067/advances024489cg.pdf
  6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society. Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405
  7. Kcentra (prothrombin complex concentrate, human) prescribing information. CSL Behring; revised 05/2023. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eee1afb8-324c-42e4-8bf0-f0c9da5e6d42
  8. Clinical and Laboratory Standards Institute. GP41: Collection of Diagnostic Venous Blood Specimens, 7th ed. Wayne, PA: CLSI; 2017. Order of draw and additive guidance.

Last updated Spotted something wrong? Report an error and include the page URL.

Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.